Clinical trial

Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC

NCT05681780

Study summary

ClinicalTrials.gov

Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC

Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE1

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

6 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

BIOLOGICAL · Unmapped registry intervention Tumor-infiltrating Lymphocytes (TIL) Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Nivolumab Normalized identity: nivolumab View linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Cyclophosphamide Normalized identity: cyclophosphamide View linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Fludarabine Normalized identity: fludarabine View linked drug · Find medicine records · Find other trials using this name

OTHER · Unmapped registry intervention Tumor-infiltrating Lymphocyte Therapy Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Interleukin-2 (IL2) Find medicine records · Find other trials using this name

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2023-03-10

PhasePHASE1

Conditions

Non Small Cell Lung Cancerunresolved

Stage IV Non-small Cell Lung Cancerunresolved

Recurrent Non Small Cell Lung Cancerunresolved

Interventions

Tumor-infiltrating Lymphocytes (TIL)BIOLOGICAL

NivolumabDRUG · verified · RxNorm: nivolumab

CyclophosphamideDRUG · verified · RxNorm: cyclophosphamide

FludarabineDRUG · verified · RxNorm: fludarabine

Tumor-infiltrating Lymphocyte TherapyOTHER

Interleukin-2 (IL2)DRUG

Sponsors & collaborators

H. Lee Moffitt Cancer Center and Research Institutelead sponsor

Mapped research locations

TampaFlorida, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05681780 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.